Metagenomi
Financing Rounds
- Series A
- Series B
Round Led by Symbiosis
Round Led by Symbiosis
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. The Company’s metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. It adapts and forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel its pipeline of novel medicines and can be leveraged by partners.
Modality
- Genetic Medicine
Indications
- Circulatory & Metabolic Disease
- Neurology
- Oncology
- Other
Development Status
- Pre-Clinical